Summary of Significant Accounting Policies - Additional Information (Detail)		1 Months Ended		12 Months Ended
	Oct. 31, 2009 shares	Nov. 30, 2016 USD ($)	Sep. 30, 2013 USD ($)	Dec. 31, 2016 USD ($) Segment Customer $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares
Schedule Of Significant Accounting Policies [Line Items]
Number of operating segments | Segment				2
Foreign currency re-measurement losses				$ 200,000	$ 70,000	$ 33,000
Common stock, shares issued | shares	1,362,500			12,257,000	12,215,000
Warrants to purchase common stock, in shares | shares	681,275
Derivative liability, fair value, gross liability						0
Expense (income) recognized on adjustment of fair value of stock warrant liability				$ 0	$ 0	(379,000)
Reserves for excess and obsolete inventory				45,000	300,000
Net of allowance for doubtful accounts				6,573,000	7,538,000
Unbilled accounts receivable				$ 1,300,000	1,900,000
Number of major customers | Customer				2
Number of reporting unit | Customer				2
Goodwill impaired				$ 0
One time payment, royalty revenues				14,297,000	3,745,000	5,599,000
Share based compensation				1,200,000	1,800,000	600,000
Unamortized share-based compensation cost related to non-vested stock options not yet recognized				$ 3,300,000
Weighted average period to recognize unamortized share-based compensation cost related to non-vested stock options				5 years 2 months 9 days
Cash received from option exercised					82,000	33,000
Stock option exercised | shares				0
Company options granted to employees, in shares | shares				657,500
Share-based compensation expense				$ 1,201,000	1,750,000	607,000
Tax benefit recognized				$ 0	$ 0	$ 0
Antidilutive securities excluded from computation of earnings per share | shares				1,658,234	1,087,308	1,692,180
Research and Development [Member]
Schedule Of Significant Accounting Policies [Line Items]
Share-based compensation expense				$ 73,000	$ 1,126,000	$ 2,000
General and Administrative [Member]
Schedule Of Significant Accounting Policies [Line Items]
Share-based compensation expense				$ 879,000	$ 507,000	533,000
Non Employees [Member]
Schedule Of Significant Accounting Policies [Line Items]
Company options granted to employees, in shares | shares				0	243,000
Share-based compensation expense				$ 100,000	$ 1,100,000	$ 0
Weighted-average grant date fair values of options granted | $ / shares					$ 4.52
Non Employees [Member] | Research and Development [Member]
Schedule Of Significant Accounting Policies [Line Items]
Company options granted to employees, in shares | shares				240,000
Employees [Member]
Schedule Of Significant Accounting Policies [Line Items]
Weighted-average grant date fair values of options granted | $ / shares				$ 4.66	$ 4.38	$ 4.27
Employee Stock Option [Member]
Schedule Of Significant Accounting Policies [Line Items]
Unamortized share-based compensation cost related to non-vested stock options not yet recognized				$ 3,300,000
Weighted average period to recognize unamortized share-based compensation cost related to non-vested stock options				2 years 9 months 29 days
Company options granted to employees, in shares | shares				657,500	387,000	312,000
Other Stock Options [Member] | Non Employees [Member]
Schedule Of Significant Accounting Policies [Line Items]
Weighted average period to recognize unamortized share-based compensation cost related to non-vested stock options				2 years 9 months
Other Stock Options [Member] | Non Employees [Member] | General and Administrative [Member]
Schedule Of Significant Accounting Policies [Line Items]
Company options granted to employees, in shares | shares				3,000
Juniper Pharma Services [Member]
Schedule Of Significant Accounting Policies [Line Items]
Assumed obligation under grant arrangement by the entity			$ 3,900,000
Juniper Pharma Services [Member] | Regional Growth Fund [Member]
Schedule Of Significant Accounting Policies [Line Items]
Assumed obligation under grant arrangement by the entity				$ 2,500,000
Allergan [Member]
Schedule Of Significant Accounting Policies [Line Items]
One time payment, royalty revenues		$ 11,000,000		$ 11,000,000
Merck KGaA [Member]
Schedule Of Significant Accounting Policies [Line Items]
Additional license and supply agreement renewals term				5 years
License and supply agreement expiration date				May 19, 2020
Minimum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life				3 years
Minimum [Member] | Merck KGaA [Member]
Schedule Of Significant Accounting Policies [Line Items]
Revenue recognition, recorded revenue cost plus percentage				20.00%
Maximum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life				7 years